The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer

Nobuhiro Hanai; Michi Sawabe; Takahiro Kimura; Hidenori Suzuki; Taijiro Ozawa; Hitoshi Hirakawa; Yujiro Fukuda; Yasuhisa Hasegawa

doi:10.18632/oncotarget.26438

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer

Nobuhiro Hanai _, Michi Sawabe, Takahiro Kimura, Hidenori Suzuki, Taijiro Ozawa, Hitoshi Hirakawa, Yujiro Fukuda and Yasuhisa Hasegawa

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:37008-37016. https://doi.org/10.18632/oncotarget.26438

Metrics: PDF 1451 views | HTML 2795 views | ?

Abstract

Nobuhiro Hanai1, Michi Sawabe1,2, Takahiro Kimura1,3, Hidenori Suzuki1, Taijiro Ozawa1,4, Hitoshi Hirakawa1,5, Yujiro Fukuda1,6 and Yasuhisa Hasegawa1,7

1Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Aichi, Japan

2Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan

3Department of Otolaryngology-Head and Neck Surgery, Nara Medical University, Nara, Japan

4Department of Otolaryngology, Toyohashi Municipal Hospital, Aichi, Japan

5Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan

6Department of Otolaryngology, Kawasaki Medical School, Okayama, Japan

7Department of Head and Neck Surgery and Otolaryngology, Asahi University Hospital, Gifu, Japan

Correspondence to:

Nobuhiro Hanai, email: [email protected]

Keywords: modified Glasgow prognostic score; high-sensitivity modified Glasgow prognostic score; head and neck cancer; C-reactive protein; survival

Received: August 06, 2018 Accepted: November 26, 2018 Published: December 11, 2018

ABSTRACT

Background: There is increasing evidence that the inflammatory indices of modified Glasgow prognostic score (mGPS) and high-sensitivity mGPS (HS-mGPS) play important roles in predicting the survival in many cancer; however, evidence supporting such an association in head and neck cancer (HNC) is scarce.

Materials and Methods: We evaluated the impact of the mGPS and HS-mGPS on the overall survival (OS) in 129 patients with HNC treated at Aichi Cancer Center Central Hospital from 2012-2013. The mGPS was calculated as follows: mGPS of 0, C-reactive protein (CRP) ≤1.0 mg/dl; 1, CRP >1.0 mg/dl; 2, CRP>1.0 mg/dl and albumin <3.5 mg/dl. Regarding the HS-mGPS, the CRP threshold level was set as 0.3 mg/dl. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated by Cox proportional hazard models after adjusting for potential confounders.

Results: The prognosis of HNC worsened significantly as both the mGPS and HS-mGPS increased in a univariate analysis. After adjusting for covariates, the HS-mGPS was significantly associated with the OS (adjusted HR for HS-mGPS of 2 compared to an HS-mGPS of 0 [HR_score2-0] 3.14 [95% CI: 1.23-8.07], P_trend < 0.001), while the mGPS was suggested to be associated with the survival (HR_score2-0 2.37 [95% CI:0.89-6.33], P_trend = 0.145). Even after stratification by clinical covariates, these associations persisted.

Conclusion: We conclude that the HS-mGPS is useful as an independent prognostic factor in HNC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26438

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer

Abstract